Status: Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Participants needed: 466

Trial details

Phase: Phase 2, Phase 3Age: 10-65Biological sex: AllType: InterventionalSponsor: Vertex Pharmaceuticals IncorporatedUpdated: Jun 25, 2026Locations: 318

Eligibility criteria

APOL1 genotype of G1/G1, G2/G2, or G1/G2 [+1]

Solid organ or bone marrow transplant [+5]

Status: Not yet recruiting

Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors

Participants needed: 20

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Brigham and Women's HospitalUpdated: May 18, 2026Locations: 1

Eligibility criteria

Adults (≥ 18 years old) with active malignancy who are currently treated with VS... [+2]

Estimated glomerular filtration rate (eGFR) < 45 ml/min/1.73m2 [+20]

Status: Recruiting

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

Participants needed: 56

Trial details

Phase: Phase 2Age: 18-68Biological sex: AllType: InterventionalSponsor: Maze TherapeuticsUpdated: Apr 17, 2026Locations: 81

Eligibility criteria

APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 [+1]

Organ or bone marrow transplantation [+4]